News

Rhein Metall’s market assessment was also revised by Mwb Research, which lowered its price target from €1,450 to €1,400 and trimmed 2027 and 2028 sales and EPS estimates by 1.8 % and 2.1 %, respectively. Nevertheless, the research firm maintained a buy rating, noting the core defense up‑cycle thesis remains intact.

Full article

Rhein Metall’s shares fell sharply – up to 17 % intraday – as analysts recalculated the impact. The company is expected to write off roughly €2 billion of costs already expended on the project, which had exceeded €18 billion in total cost estimates and more than €2 billion spent since June 2020. Naval revenue guidance is being reset from €5 billion...

Full article

On Wednesday, Germany announced it would scrap the F126 anti‑submarine frigate program, a decision that has reverberated across Rhein Metall’s operations and the broader European defense sector. The cancellation, driven by significant delays, cost increases and contractor risk, meant the company lost a €12.8 billion contract in which it had been sl...

Full article

The global Crohn's disease therapeutics market is projected to grow at a CAGR of 2.7% from 2024 to 2030, according to Grandview Research. The company currently has cash and cash equivalents totaling €116.5 million as of December 31, 2025. AGMB shares closed Tuesday's trade at $11.94, up 0.84%.

Full article

AgomAb expects to enroll up to 320 patients globally in the trial, with participants being randomized to receive ontunisertib at one of three dose levels or a matching placebo. The company has submitted the design to the FDA and has received Central Institutional Review Board (IRB) clearance in the U.S., as well as approval from Health Canada.

Full article

The NOV-ERA trial has been aligned with the U.S. FDA, which previously granted Fast Track Designation to Ontunisertib for Fibrostenosing Crohn's disease. The primary efficacy endpoint of the study will be endoscopic passability at Week 24, measured by the SES-CD narrowing score.

Full article

AgomAb Therapeutics NV (AGMB) has announced the study design of the Phase 2b NOV-ERA trial for Ontunisertib in treating Fibrostenosing Crohn's Disease. The trial will evaluate the efficacy and safety of ontunisertib, an oral small molecule that inhibits ALK5/TGF-β in the GI tract. This is a significant development as there are currently no approved...

Full article

With its technology gaining media attention, SMX is poised to capitalize on the emerging trend of proof‑driven sustainability, where data replaces promises. The company's molecular marking and verification platform can provide the necessary solution for companies and governments looking to increase confidence in their sourcing decisions and comply...

Full article

The growing importance of recycling is driven by material scarcity, geopolitical risk, supply‑chain fragmentation, and demand for traceability. SMX's platform can help transform recycled plastic from a discounted commodity into a contractable, compliant, and commercially valuable material asset. As the market shifts towards a more circular economy,...

Full article

By embedding markers directly into raw materials, products, and recycled inputs, SMX creates a certified record that follows materials across production, use, recovery, recycling, and reuse. This verification technology enables companies and governments to track the origin, quality, and compliance of materials, thereby increasing confidence in thei...

Full article